Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 960903

The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients


Skelin, Marko; Javor, Eugen; Lucijanić, Marko; Lucijanić, Tomo; Jakupović, Lejsa; Rahelić, Dario
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients // International journal of clinical practice, 72 (2018), 12; e13274-e13274 doi:10.1111/ijcp.13274 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 960903 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients

Autori
Skelin, Marko ; Javor, Eugen ; Lucijanić, Marko ; Lucijanić, Tomo ; Jakupović, Lejsa ; Rahelić, Dario

Izvornik
International journal of clinical practice (1368-5031) 72 (2018), 12; E13274-e13274

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
type 2 diabetes, cardiovascular mortality, postprandial glucagon, empagliflozin, liraglutide, semaglutide

Sažetak
Aim: Type 2 diabetes (T2D) is one of the major public health issues worldwide. The main cause of mortality and morbidity among T2D patients are cardiovascular (CV) causes. Various antidiabetics are used in T2D treatment, but until recently they lacked clear evidence of the reduction of CV mortality and all-cause mortality as independent study endpoints. The aim of this article is to present and critically evaluate potential mechanisms behind the remarkable results documented in trials with new antidiabetics for the treatment of T2D. Methods: Relevant data were collected by using the MEDLINE, PubMed, EMBASE, Web of Science, Science Direct, and Scopus databases with the key words: „type 2 diabetes, “ “mortality, ” “glucagon, ” “empagliflozin, ” “liraglutide, ” “insulin, ” and “QTc.” Searches were not limited to specific publication types or study designs. Results: The EMPA-REG OUTCOME trial with empagliflozin and LEADER trial with liraglutide presented remarkable results regarding the reduction of mortality in T2D treatment. However, the potential mechanism for those beneficial effects is difficult to determine. It is not likely that improvements in classic CV risk factors are responsible for the observed effect. A potential mechanism may be caused by the elevation of postprandial (PP) glucagon concentrations that can be seen with an empagliflozin and liraglutide therapy which could have beneficial effects considering the myocardial electrical stability in T2D patients. Conclusion: This hypothesis throws new light upon possible mechanisms of reduction of mortality in T2D patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Opća bolnica Šibenik,
Klinička bolnica "Dubrava"

Profili:

Avatar Url Marko Lucijanić (autor)

Avatar Url Tomo Lucijanić (autor)

Avatar Url Dario Rahelić (autor)

Avatar Url Marko Skelin (autor)

Citiraj ovu publikaciju

Skelin, Marko; Javor, Eugen; Lucijanić, Marko; Lucijanić, Tomo; Jakupović, Lejsa; Rahelić, Dario
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients // International journal of clinical practice, 72 (2018), 12; e13274-e13274 doi:10.1111/ijcp.13274 (međunarodna recenzija, članak, znanstveni)
Skelin, M., Javor, E., Lucijanić, M., Lucijanić, T., Jakupović, L. & Rahelić, D. (2018) The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. International journal of clinical practice, 72 (12), e13274-e13274 doi:10.1111/ijcp.13274.
@article{article, year = {2018}, pages = {e13274-e13274}, DOI = {10.1111/ijcp.13274}, keywords = {type 2 diabetes, cardiovascular mortality, postprandial glucagon, empagliflozin, liraglutide, semaglutide}, journal = {International journal of clinical practice}, doi = {10.1111/ijcp.13274}, volume = {72}, number = {12}, issn = {1368-5031}, title = {The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients}, keyword = {type 2 diabetes, cardiovascular mortality, postprandial glucagon, empagliflozin, liraglutide, semaglutide} }
@article{article, year = {2018}, pages = {e13274-e13274}, DOI = {10.1111/ijcp.13274}, keywords = {type 2 diabetes, cardiovascular mortality, postprandial glucagon, empagliflozin, liraglutide, semaglutide}, journal = {International journal of clinical practice}, doi = {10.1111/ijcp.13274}, volume = {72}, number = {12}, issn = {1368-5031}, title = {The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients}, keyword = {type 2 diabetes, cardiovascular mortality, postprandial glucagon, empagliflozin, liraglutide, semaglutide} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font